COVID-19时代癌症发热性中性粒细胞减少风险评估的挑战:MASCC立场文件
该MASCC立场文件描述了COVID-19大流行期间癌症患者(尤其接受抗癌治疗者)的管理。呼吸困难是癌症患者常见急诊表现,鉴别诊断包括肺栓塞、胸膜疾病、淋巴管炎和感染,SARS-CoV-2是当前需考虑的病原体。筛查访谈以确定患者是否可能感染COVID-19对防止感染传播至关重要,尤其在医疗机构内。无症状或症状轻微的阳性癌症患者可居家监测,远程医疗是随访选择。低危发热性中性粒细胞减少的门诊管理是安全有效的策略;MASCC评分虽未在疑似或确诊SARS-CoV-2患者中验证,但在多种感染性疾病中表现良好,预期在COVID-19临床环境中有效。
要点
- 低危发热性中性粒细胞减少患者门诊管理是安全有效的策略,适用于COVID-19大流行期间减少医院就诊。
- MASCC评分尚未在疑似或确诊SARS-CoV-2患者中验证,但在多种感染性疾病中表现良好,作者认为预期在COVID-19临床环境中有效。
- 癌症患者COVID-19检测阳性且无症状或症状轻微者可居家监测,远程医疗是避免暴露的随访选择。
- 筛查访谈以确定患者是否可能感染COVID-19对防止感染传播至关重要,尤其在医疗机构内。
- 呼吸困难在癌症患者中鉴别诊断包括肺栓塞、胸膜疾病、淋巴管炎和感染,SARS-CoV-2是当前需考虑的病原体。
适用人群与场景
- 癌症患者,尤其是正在接受抗癌治疗的患者,处于COVID-19大流行期间。
- COVID-19检测阳性但无症状或症状轻微的癌症患者可居家监测。
- 表现为发热性中性粒细胞减少的癌症患者,需进行风险分层以决定门诊或住院管理。
诊断标准与关键阈值
- MASCC评分尚未在疑似或确诊SARS-CoV-2患者中验证,但在多种感染性疾病中表现良好。
处置流程与药物剂量
- 筛查访谈以确定患者是否可能感染COVID-19,以防止感染传播,尤其在医疗机构内。
- COVID-19检测阳性且无症状或症状轻微的癌症患者可居家监测。
- 远程医疗是随访患者而不造成潜在暴露的一种选择。
- 低危发热性中性粒细胞减少患者可门诊管理,该策略安全有效。
- 发热性中性粒细胞减少患者的风险分层需基于MASCC评分及其他国家和国际指南,并获取当地制定的服务。
- 创新肿瘤服务需利用远程医疗、家庭医院和门诊护理服务,以限制医院就诊次数并预见抗癌治疗的并发症。
红旗征与不能漏的情况
- 呼吸困难是癌症患者常见急诊表现,鉴别诊断包括肺栓塞、胸膜疾病、淋巴管炎和感染,SARS-CoV-2是当前需考虑的病原体。
研究设计与关键结果
- 该MASCC立场文件描述了COVID-19大流行期间癌症患者(尤其接受抗癌治疗者)的管理。
- 文件指出癌症患者COVID-19感染更严重且相关并发症更多的风险更高。
- 低危发热性中性粒细胞减少的门诊管理是安全有效的策略。
- MASCC评分虽未在疑似或确诊SARS-CoV-2患者中验证,但在多种感染性疾病中表现良好,作者认为预期在COVID-19临床环境中有效。
证据类型、等级与局限
- 证据类型:MASCC立场文件(专家意见)。
- 局限:原文未报告局限性
对床旁实践的改变
- 对癌症发热患者进行筛查访谈以确定COVID-19感染可能性,防止在医疗机构内传播。
- COVID-19阳性且无症状或症状轻微的癌症患者可居家监测,并通过远程医疗随访。
- 低危发热性中性粒细胞减少患者可考虑门诊管理,作者认为该策略安全有效。
- 发热性中性粒细胞减少的风险分层应基于MASCC评分及其他国家和国际指南,并利用当地制定的服务。
- 作者认为创新肿瘤服务需利用远程医疗、家庭医院和门诊护理服务,以限制医院就诊并预见抗癌治疗并发症。
指南或共识出处
- MASCC立场文件:Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper(Support Care Cancer)
提炼说明
- 本条依据论文摘要整理;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Patients with cancer are at higher risk of more severe COVID-19 infection and have more associated complications. The position paper describes the management of cancer patients, especially those receiving anticancer treatment, during the COVID-19 pandemic. Dyspnea is a common emergency presentation in patients with cancer with a wide range of differential diagnoses, including pulmonary embolism, pleural disease, lymphangitis, and infection, of which SARS-CoV-2 is now a pathogen to be considered. Screening interviews to determine whether patients may be infected with COVID-19 are imperative to prevent the spread of infection, especially within healthcare facilities. Cancer patients testing positive with no or minimal symptoms may be monitored from home. Telemedicine is an option to aid in following patients without potential exposure. Management of complications of systemic anticancer treatment, such as febrile neutropenia (FN), is of particular importance during the COVID-19 pandemic where clinicians aim to minimize patients' risk of infection and need for hospital visits. Outpatient management of patients with low-risk FN is a safe and effective strategy. Although the MASCC score has not been validated in patients with suspected or confirmed SARS-CoV-2, it has nevertheless performed well in patients with a range of infective illnesses and, accordingly, it is reasonable to expect efficacy in the clinical setting of COVID-19. Risk stratification of patients presenting with FN is a vital tenet of the evolving sepsis and pandemic strategy, necessitating access to locally formulated services based on MASCC and other national and international guidelines. Innovative oncology services will need to utilize telemedicine, hospital at home, and ambulatory care services approaches not only to limit the number of hospital visits but also to anticipate the complications of the anticancer treatments.
参考来源
- Cooksley T, Font C, Scotte F, et al. Emerging challenges in the evaluation of fever in cancer patients at risk of febrile neutropenia in the era of COVID-19: a MASCC position paper. Support Care Cancer. 2020. PMID: 33230644. doi:10.1007/s00520-020-05906-y
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。